Clinical Activity and Safety of Novel BRAF Inhibitor Plixorafenib (FORE8394; PLX8394) in Advanced TC Harboring BRAF Alterations

September 16, 2025 5:54 AM EDT

Read More

Press Release Sep 12 2025 FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting Read more

Press Release Aug 27 2025 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release May 27 2025 FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference Read more